Serif Bio­med­i­cines, Inc.

Serif Bio­med­i­cines, Inc. is a US-based biotechnology company focused on advancing genetic medicines through innovative technologies that program nucleic acids to function therapeutically within the human body. Founded in 2021 in Cambridge, US, Serif Biomedicines is dedicated to developing advanced genetic therapies. The company has successfully secured USD 50.

00 mn in a recent funding round from Flagship Pioneering, following its single deal to date. The founder's history is not publicly documented, and there are no references to subsidiaries or significant business pivots. Serif Biomedicines specializes in advancing genetic medicines through its innovative technology, which enables the programming of nucleic acids to function within the human body. The company’s core offerings are centered around modified DNA molecules designed to act as therapeutic agents, effectively transforming DNA into medicine.

This approach allows for previously unattainable treatment possibilities, enhancing the scope of genetic therapies available in the market. The primary customer base consists of pharmaceutical companies and research institutions globally, particularly in North America and Europe, where demand for novel therapeutic approaches is on the rise. Additionally, end-users include healthcare providers and patients seeking treatments for genetic disorders and other medical conditions, thereby addressing significant unmet health needs. The revenue model of Serif Biomedicines is predicated on strategic partnerships with pharmaceutical companies and direct collaborations with research institutions.

Transactions typically involve long-term agreements for the development and commercialization of their modified DNA therapies, allowing for shared financial responsibilities and risk mitigation. The pricing structure encompasses tiered licensing agreements based on the scale and scope of usage, with additional revenue streams generated through joint ventures for clinical trials and product development. Flagship products are positioned within this framework, offering unique therapeutic solutions tailored to specific genetic conditions. The structured collaboration between Serif Biomedicines and its partners ensures a steady flow of revenue generated from both initial licensing fees and milestone payments throughout the product development lifecycle.

In April 2026, Serif Biomedicines, Inc. raised USD 50. 00 mn in venture funding from Flagship Pioneering. The company will utilize this funding to further develop its modified DNA platform and advance its initial drug discovery programs, including preparing and presenting preclinical data at upcoming scientific meetings.

Plans include the design and launch of new products aimed at addressing unmet health needs, with specific focuses on expanding into markets across North America and Europe by 2027.